Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BCAB NASDAQ:CMMB NASDAQ:CYCC NYSE:NNVC On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBCABBioAtla$0.39-2.3%$0.41$0.24▼$2.53$23.01M0.91901,333 shs900,547 shsCMMBChemomab Therapeutics$1.14-0.9%$1.25$0.87▼$2.55$21.69M0.43223,344 shs167,180 shsCYCCCyclacel Pharmaceuticals$8.20-33.5%$15.89$3.08▼$597.60$19.54M0.03323,586 shs3.53 million shsNNVCNanoViricides$1.60+9.6%$1.46$0.94▼$2.55$25.72M0.88236,588 shs557,051 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBCABBioAtla-2.26%-0.72%-3.75%+18.90%-81.22%CMMBChemomab Therapeutics-0.87%-2.56%-7.32%+1.79%+1.79%CYCCCyclacel Pharmaceuticals-33.50%+119.84%+60.31%-84.89%-98.05%NNVCNanoViricides+9.59%+14.29%+10.34%+20.30%-21.57%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBCABBioAtla2.3767 of 5 stars3.31.00.00.03.32.50.6CMMBChemomab Therapeutics2.7849 of 5 stars3.53.00.00.02.71.70.6CYCCCyclacel Pharmaceuticals1.2565 of 5 stars0.05.00.00.02.81.70.0NNVCNanoViricides0.361 of 5 stars0.03.00.00.03.10.00.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBCABBioAtla 2.50Moderate Buy$5.001,198.70% UpsideCMMBChemomab Therapeutics 3.00Buy$8.50645.61% UpsideCYCCCyclacel Pharmaceuticals 2.00HoldN/AN/ANNVCNanoViricides 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest CYCC, NNVC, BCAB, and CMMB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/16/2025CMMBChemomab TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$11.00 ➝ $10.00(Data available from 7/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBCABBioAtla$11M2.04N/AN/A$0.25 per share1.54CMMBChemomab TherapeuticsN/AN/AN/AN/A$0.72 per shareN/ACYCCCyclacel Pharmaceuticals$40K323.90N/AN/A($58.87) per share-0.14NNVCNanoViricidesN/AN/AN/AN/A$0.66 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBCABBioAtla-$69.78M-$1.22N/AN/AN/AN/A-373.47%-116.55%8/6/2025 (Estimated)CMMBChemomab Therapeutics-$13.94M-$0.76N/AN/AN/AN/A-106.70%-82.18%8/20/2025 (Estimated)CYCCCyclacel Pharmaceuticals-$11.21M-$839.58N/A∞N/AN/A-3,648.09%-155.99%8/13/2025 (Estimated)NNVCNanoViricides-$8.29M-$0.70N/A∞N/AN/A-87.90%-78.69%N/ALatest CYCC, NNVC, BCAB, and CMMB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025CMMBChemomab Therapeutics-$0.20-$0.14+$0.06-$0.14N/AN/A5/6/2025Q1 2025BCABBioAtla-$0.28-$0.29-$0.01-$0.26N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBCABBioAtlaN/AN/AN/AN/AN/ACMMBChemomab TherapeuticsN/AN/AN/AN/AN/ACYCCCyclacel PharmaceuticalsN/AN/AN/AN/AN/ANNVCNanoViricidesN/AN/AN/AN/AN/ALatest CYCC, NNVC, BCAB, and CMMB DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date4/28/2025CYCCCyclacel Pharmaceuticals$36.004/29/20254/29/20255/1/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBCABBioAtlaN/A2.352.35CMMBChemomab TherapeuticsN/A5.335.33CYCCCyclacel PharmaceuticalsN/A5.605.60NNVCNanoViricidesN/A3.442.47Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBCABBioAtla77.23%CMMBChemomab Therapeutics46.05%CYCCCyclacel Pharmaceuticals23.58%NNVCNanoViricides10.30%Insider OwnershipCompanyInsider OwnershipBCABBioAtla11.50%CMMBChemomab Therapeutics11.91%CYCCCyclacel Pharmaceuticals51.20%NNVCNanoViricides4.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBCABBioAtla6058.42 million51.70 millionOptionableCMMBChemomab Therapeutics2018.86 million16.61 millionNot OptionableCYCCCyclacel Pharmaceuticals141.58 million773,000OptionableNNVCNanoViricides2016.07 million14.92 millionOptionableCYCC, NNVC, BCAB, and CMMB HeadlinesRecent News About These CompaniesWHO Extended Global Emergency Status of MPox Epidemic – Development of Treatment for MPox with NV-387 is Timely, Says NanoViricidesJuly 16 at 4:06 PM | azcentral.comANanoViricides says MPox drug candidate NV-387 poised for Phase II trial as WHO extends global health emergencyJuly 16 at 9:16 AM | proactiveinvestors.comWHO Extended Global Emergency Status of MPox Epidemic - Development of Treatment for MPox with NV-387 is Timely, Says NanoViricidesJuly 16 at 8:30 AM | accessnewswire.comANanoViricides positioned at forefront of Mpox treatment efforts, says ZacksJuly 15 at 12:42 PM | proactiveinvestors.comNanoViricides positioned at forefront of Mpox treatment efforts, says ZacksJuly 15 at 12:29 PM | proactiveinvestors.comNNVC: NanoViricides Set to Initiate Phase 2 Trial in MPoxJuly 15 at 11:52 AM | finance.yahoo.comNanoViricides nears completion of clinical trial design for MPox treatmentJuly 14 at 8:52 AM | proactiveinvestors.comAdaptive Clinical Protocol Design for Phase II MPox Clade I Treatment with a Novel Broad-Spectrum Drug NV-387 is Almost Complete, Reports NanoViricidesJuly 14 at 7:42 AM | markets.businessinsider.comNanoViricides (NNVC) Accelerates MPox Drug Development, Citing Strong Business and Public Health CaseJuly 7, 2025 | theglobeandmail.comNanoViricides advances antiviral candidate NV-387 into Phase 2 trials for MpoxJuly 2, 2025 | proactiveinvestors.comNanoViricides Inc.June 19, 2025 | barrons.comNanoViricides touts antiviral NV-387 as tool against new COVID variantJune 18, 2025 | proactiveinvestors.comWith Rising Variants of COVID and Bird Flu, the Single Broad-Spectrum Antiviral NV-387 Would be the Best Partner for Preparedness, Says NanoViricides' Dr. DiwanJune 18, 2025 | accessnewswire.comANanoViricides measles drug development animal study imminentJune 4, 2025 | msn.comNanoViricides commissions animal study of broad-spectrum antiviral for measlesJune 4, 2025 | proactiveinvestors.comNanoViricides Measles Drug Development Animal Study is ImminentJune 4, 2025 | accessnewswire.comANanoViricides to Present at the BIO International Convention in Boston on Monday, June 16, 2025May 28, 2025 | accessnewswire.comANanoViricides president backs FDA's targeted COVID booster policy shiftMay 22, 2025 | proactiveinvestors.comThe New Rational FDA COVID Vaccine Policy is Long Overdue, Says NanoViricides’ Dr. DiwanMay 22, 2025 | miamiherald.comMThe New Rational FDA COVID Vaccine Policy is Long Overdue, Says NanoViricides' Dr. DiwanMay 22, 2025 | accessnewswire.comANew MarketBeat Followers Over TimeMedia Sentiment Over TimeCYCC, NNVC, BCAB, and CMMB Company DescriptionsBioAtla NASDAQ:BCAB$0.38 -0.01 (-2.26%) Closing price 07/16/2025 04:00 PM EasternExtended Trading$0.37 -0.01 (-3.12%) As of 07:14 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck. It is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody, which is in Phase II clinical trial for treating melanoma, carcinomas, and NSCLC; and BA3182, a bispecific candidate that is in Phase 1 study for the treatment of adenocarcinomas, as well as BA3361, which is in preclinical studies for treating multiple tumor types. The company was founded in 2007 and is headquartered in San Diego, California.Chemomab Therapeutics NASDAQ:CMMB$1.14 -0.01 (-0.87%) Closing price 07/16/2025 03:59 PM EasternExtended Trading$1.14 0.00 (0.00%) As of 07/16/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody had completed Phase 2a clinical trials that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021. Chemomab Therapeutics Ltd. was founded in 2011 and is based in Tel Aviv, Israel.Cyclacel Pharmaceuticals NASDAQ:CYCC$8.20 -4.13 (-33.50%) Closing price 07/16/2025 04:00 PM EasternExtended Trading$8.32 +0.13 (+1.52%) As of 07:21 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies. It has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. The company was founded in 1996 and is headquartered in Berkeley Heights, New Jersey.NanoViricides NYSE:NNVC$1.60 +0.14 (+9.59%) Closing price 07/16/2025 04:00 PM EasternExtended Trading$1.62 +0.02 (+1.56%) As of 07/16/2025 07:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company's product portfolio includes NV-CoV-2, nanoviricide drug which is in phase 1a/1b clinical trails for the treatment of Covid; and NV-CoV-2 Oral Syrup, and NV-CoV-2 Oral Gummies, a semi-solid fixed-dose form which are in phase 1a/1b human clinical trials for enabling body-weight-based dose titration as is required for pediatric cases. It also offers NV-CoV-2 Solution for injection, infusion, and inhalation to treat severe cases that are not yet hospitalized would be best performed by an injection; and injectable solution can be delivered directly into the lungs as a fog created using standard portable battery operated nebulizer devices which enables action at the most important site of infection by a respiratory virus, such as coronaviruses, RSV, influenzas, human meta-pneumovirus, certain adenoviruses, and other infections, that can lead to severe pneumonia. In addition, the company provides Nanoviricide, a biomimetic platform technology designed to attack enveloped virus particles to deliver anti-viral payload into infected cells sparing uninfected cells to block replication cycle without toxicity. NanoViricides, Inc. was incorporated in 2005 and is headquartered in Shelton, Connecticut. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas AMD Just Triggered a Signal Traders Can’t Ignore JNJ’s Stock Price Is Back in Rally Mode—The Time to Buy Is Now This ASML Dip Could Be Gone Before You Know It—Don’t Miss Out Rocket Lab Gets New Street-High Price Target from Citi Super Micro Stock May Benefit as Cooling Demand Takes Off Pelosi Makes Big Bet on Broadcom—Here’s Why It Matters 3 Analysts Set $600 Target Ahead of Microsoft Earnings Salesforce Stock Set for 30% Upside to Reach New Highs Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
